Market Research Logo

Nicotine Addiction - Pipeline Review, H2 2016

Nicotine Addiction - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Nicotine Addiction - Pipeline Review, H2 2016’, provides an overview of the Nicotine Addiction pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Nicotine Addiction, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Nicotine Addiction and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

  • Certain sections in the report may be removed or altered based on the availability and relevance of data.


  • Scope
    • The report provides a snapshot of the global therapeutic landscape of Nicotine Addiction
    • The report reviews pipeline therapeutics for Nicotine Addiction by companies and universities/research institutes based on information derived from company and industry-specific sources
    • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    • The report reviews key players involved Nicotine Addiction therapeutics and enlists all their major and minor projects
    • The report assesses Nicotine Addiction therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
    • The report summarizes all the dormant and discontinued pipeline projects
    • The report reviews latest news related to pipeline therapeutics for Nicotine Addiction
    Reasons to buy
    • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    • Identify and understand important and diverse types of therapeutics under development for Nicotine Addiction
    • Identify potential new clients or partners in the target demographic
    • Develop strategic initiatives by understanding the focus areas of leading companies
    • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
    • Devise corrective measures for pipeline projects by understanding Nicotine Addiction pipeline depth and focus of Indication therapeutics
    • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


    Introduction
    Global Markets Direct Report Coverage
    Nicotine Addiction Overview
    Therapeutics Development
    Pipeline Products for Nicotine Addiction - Overview
    Pipeline Products for Nicotine Addiction - Comparative Analysis
    Nicotine Addiction - Therapeutics under Development by Companies
    Nicotine Addiction - Therapeutics under Investigation by Universities/Institutes
    Nicotine Addiction - Pipeline Products Glance
    Clinical Stage Products
    Early Stage Products
    Nicotine Addiction - Products under Development by Companies
    Nicotine Addiction - Products under Investigation by Universities/Institutes
    Nicotine Addiction - Companies Involved in Therapeutics Development
    Addex Therapeutics Ltd
    Astraea Therapeutics, LLC
    Cerecor Inc.
    Chronos Therapeutics Limited
    Embera NeuroTherapeutics, Inc.
    Hager Biosciences, LLC
    Heptares Therapeutics Limited
    Omeros Corporation
    Nicotine Addiction - Therapeutics Assessment
    Assessment by Monotherapy Products
    Assessment by Combination Products
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Drug Profiles
    (metyrapone + oxazepam) - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ADX-71441 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    AT-1001 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    CERC-501 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    EORA-101 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    OMS-405 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    OMS-527 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecule for Nicotine Addiction - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecule for Psychiatric Disorders - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecule to Antagonize Orexin 1 for Central Nervous System Disorders - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Antagonize Alpha-4 Beta-2 Nicotinic Acetylcholine Receptor for CNS Disorders - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Antagonize CRF-R1 and OREXIN-1 for Nicotine Addiction - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Inhibit Dopamine Transporter for CNS and Metabolic Disorders - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Inhibit Dopamine, Serotonin, Norepinephrine Transporters for Central Nervous System Disorders - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    URB-694 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Vaccine for Nicotine Addiction - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Vaccine for Nicotine Addiction - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Vaccine for Nicotine Addiction - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Vaccine for Nicotine Addiction - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Nicotine Addiction - Dormant Projects
    Nicotine Addiction - Discontinued Products
    Nicotine Addiction - Product Development Milestones
    Featured News & Press Releases
    Dec 11, 2015: Publication Reports Human Brain Penetration and Target Engagement of Cerecor’s Oral Kappa Opioid Receptor Antagonist, CERC-501
    Jul 10, 2014: Addex ADX71441 Positive Results in Preclinical Model of Nicotine Addiction
    Mar 19, 2013: Omeros Elucidates Mechanism Of PDE7 Inhibitors In Addiction
    Feb 16, 2012: Molecular Express announces award of STTR Phase I funding from the National Institutes of Health to develop a liposomal nicotine vaccine
    May 05, 2011: Omeros Announces Expansion Of Potential Indications For PDE7 Inhibitors
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer
    List of Tables
    Number of Products under Development for Nicotine Addiction, H2 2016
    Number of Products under Development for Nicotine Addiction - Comparative Analysis, H2 2016
    Number of Products under Development by Companies, H2 2016
    Number of Products under Investigation by Universities/Institutes, H2 2016
    Comparative Analysis by Clinical Stage Development, H2 2016
    Comparative Analysis by Early Stage Development, H2 2016
    Products under Development by Companies, H2 2016
    Products under Investigation by Universities/Institutes, H2 2016
    Nicotine Addiction - Pipeline by Addex Therapeutics Ltd, H2 2016
    Nicotine Addiction - Pipeline by Astraea Therapeutics, LLC, H2 2016
    Nicotine Addiction - Pipeline by Cerecor Inc., H2 2016
    Nicotine Addiction - Pipeline by Chronos Therapeutics Limited, H2 2016
    Nicotine Addiction - Pipeline by Embera NeuroTherapeutics, Inc., H2 2016
    Nicotine Addiction - Pipeline by Hager Biosciences, LLC, H2 2016
    Nicotine Addiction - Pipeline by Heptares Therapeutics Limited, H2 2016
    Nicotine Addiction - Pipeline by Omeros Corporation, H2 2016
    Assessment by Monotherapy Products, H2 2016
    Assessment by Combination Products, H2 2016
    Number of Products by Stage and Target, H2 2016
    Number of Products by Stage and Mechanism of Action, H2 2016
    Number of Products by Stage and Route of Administration, H2 2016
    Number of Products by Stage and Molecule Type, H2 2016
    Nicotine Addiction - Dormant Projects, H2 2016
    Nicotine Addiction - Discontinued Products, H2 2016
    List of Figures
    Number of Products under Development for Nicotine Addiction, H2 2016
    Number of Products under Development for Nicotine Addiction - Comparative Analysis, H2 2016
    Number of Products under Development by Companies, H2 2016
    Comparative Analysis by Early Stage Products, H2 2016
    Assessment by Monotherapy Products, H2 2016
    Number of Products by Top 10 Targets, H2 2016
    Number of Products by Stage and Top 10 Targets, H2 2016
    Number of Products by Top 10 Mechanism of Actions, H2 2016
    Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
    Number of Products by Stage and Routes of Administration, H2 2016
    Number of Products by Molecule Types, H2 2016
    Number of Products by Stage and Molecule Types, H2 2016

    Download our eBook: How to Succeed Using Market Research

    Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

    Download eBook

    Share this report